Abstract:Background: Colchicine has been approved to reduce cardiovascular risk in patients with coronary heart disease on the basis of its potential benefits demonstrated in the COLCOT (Colchicine Cardiovascular Outcomes Trial) and LoDoCo2 (Low-Dose Colchicine 2) studies. Nevertheless, there are limited data available about the specific impact of colchicine on coronary plaques. Methods: This was a prospective, single-center, randomized, double-blind clinical trial. From May 3, 2021, until August 31, 2022, a total of 128 patients with acute coronary syndrome aged 18 to 80 years with lipid-rich plaque (lipid pool arc >90°) detected by optical coherence tomography were included. The subjects were randomly assigned in a 1:1 ratio to receive either colchicine (0.5 mg once daily) or placebo for 12 months. The primary end point was the change in the minimal fibrous cap thickness from baseline to the 12-month follow-up. Results: Among 128 patients, 52 in the colchicine group and 52 in the placebo group completed the study. The mean age of the 128 patients was 58.0±9.8 years, and 25.0% were female. Compared with placebo, colchicine therapy significantly increased the minimal fibrous cap thickness (51.9 [95% CI, 32.8 to 71.0] μm versus 87.2 [95% CI, 69.9 to 104.5] μm; difference, 34.2 [95% CI, 9.7 to 58.6] μm; P=0.006), and reduced average lipid arc (-25.2° [95% CI, -30.6° to -19.9°] versus -35.7° [95% CI, -40.5° to -30.8°]; difference, -10.5° [95% CI, -17.7° to -3.4°]; P=0.004), mean angular extension of macrophages (-8.9° [95% CI, -13.3° to -4.6°] versus -14.0° [95% CI, -18.0° to -10.0°]; difference, -6.0° [95% CI, -11.8° to -0.2°]; P=0.044), high-sensitivity C-reactive protein level (geometric mean ratio, 0.6 [95% CI, 0.4 to 1.0] versus 0.3 [95% CI, 0.2 to 0.5]; difference, 0.5 [95% CI, 0.3 to 1.0]; P=0.046), interleukin-6 level (geometric mean ratio, 0.8 [95% CI, 0.6 to 1.1] versus 0.5 [95% CI, 0.4 to 0.7]; difference, 0.6 [95% CI, 0.4 to 0.9]; P=0.025), and myeloperoxidase level (geometric mean ratio, 1.0 [95% CI, 0.8 to 1.2] versus 0.8 [95% CI, 0.7 to 0.9]; difference, 0.8 [95% CI, 0.6 to 1.0]; P=0.047). Conclusions: Our findings suggested that colchicine resulted in favorable effects on coronary plaque stabilization at optical coherence tomography in patients with acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04848857.

Inhibition of CYP1A1 Alleviates Colchicine-Induced Hepatotoxicity

Metabolomics reveals that sulfotransferase 1 may regulate colchicine-induced liver injury

Comprehensive Multi-Omics Analysis Elucidates Colchicine-Induced Toxicity Mechanisms and Unveils the Therapeutic Potential of MLN4924 and Kinase Inhibitors

A New Insight into Toxicity of Colchicine Analogues by Molecular Docking Analysis Based on Intestinal Tight Junction Protein ZO-1

A new insight into mechanism of colchicine poisoning based on untargeted metabolomics

Identification of Glycine Receptor Α3 As a Colchicine-Binding Protein.

Colchicine Increases Intestinal Toxic Load by Disturbing Fecal Metabolome Homeostasis in Mice

Colchicine Increases Intestinal Permeability, Suppresses Inflammatory Responses, and Alters Gut Microbiota in Mice.

Colchicine disrupts bile acid metabolic homeostasis by affecting the enterohepatic circulation in mice

Colchicine Alleviates Cholesterol Crystal-Induced Endothelial Cell Pyroptosis through Activating AMPK/SIRT1 Pathway

Colchicine-induced Apoptosis in Human Normal Liver L-02 Cells by Mitochondrial Mediated Pathways.

Study of the Mechanism of Liver Injury Induced by Colchicin

Colchicine in Renal Medicine: New Virtues of an Ancient Friend

Combination of Colchicine and Ticagrelor Inhibits Carrageenan-Induced Thrombi in Mice

Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)

Colchicine Inhibited the Expression of Tissue Inhibitor of Metalloprotenase-1 and Interleukin-6 in Cultured Activated Hepatic Stellate Cells

Study on the mechanism of action of colchicine in the treatment of coronary artery disease based on network pharmacology and molecular docking technology

Acute oral colchicine caused gastric mucosal injury and disturbance of associated microbiota in mice

Colchicine Inhibits Monosodium Urate Crystal-Mediated Inflammation by Influencing F-actin Formation

Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review

Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial